NCNA_OUT_1 [2025-03-27 16:23:09 -0400] 2204 Bytes | 632 tokens | Cum: 632 tkns (7.90% of 8k)
==========================================================================

We need a winner today and it's already 4:23:07 PM on Thu Mar 27, 2025 -0400 ... So let's find out if NuCana (NCNA) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 1.07 up from 0.83. Is there something here we can get excited about? Help me analyze.

Here's the first list of news for NuCana:

C1 - Mar-20-25 04:01PM - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
C2 - Nov-25-24 07:00AM - NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update
C3 - Nov-11-24 07:00AM - NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
C4 - Oct-04-24 01:03PM - Baillie Gifford's Strategic Acquisition of NuCana PLC Shares
C5 - Sep-25-24 04:01PM - NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
C6 - Sep-16-24 09:24AM - NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
C7 - Sep-14-24 03:01AM - NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
C8 - Aug-30-24 08:47AM - NuCana Stock Plunges On Colorectal Combo Therapy Trial Setback, Ends Mid-Stage Study After Disappointing Data

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on NuCana (NCNA)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

NCNA_OUT_3 [2025-03-27 16:23:18 -0400] 1099 Bytes | 341 tokens | Cum: 975 tkns (12.19% of 8k)
==========================================================================

Showing C1 (chunk 1 of 12): C1:
**NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update**
Date: Mar-20-25 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046697/0/en/NuCana-Reports-Fourth-Quarter-and-Year-End-2024-Financial-Results-and-Provides-Business-Update.html

March 20, 2025 16:01 ET| Source:NuCana plcNuCana plc

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025

Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738

Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab

EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2024

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NCNA_OUT_5 [2025-03-27 16:23:20 -0400] 895 Bytes | 245 tokens | Cum: 1342 tkns (16.78% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T20:25:06Z - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update...
A2 - 2025-03-20T20:01:49Z - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - NuC...
A3 - 2025-03-20T20:10:00Z - NuCana plc: NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business ...
A4 - 2025-03-20T20:08:23Z - NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NCNA_OUT_7 [2025-03-27 16:23:27 -0400] 1099 Bytes | 324 tokens | Cum: 1668 tkns (20.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 16): A1:
**NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update**Date: 2025-03-20Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/03/21/tmt-newswire/globenewswire/nucana-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-business-update/2077383Vaxart Provides Business Update and Reports Full Year 2024 Financial Results

Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025

Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC-7738

Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab

Anticipated Cash Runway Extended into Q3 2025

EDINBURGH, United Kingdom, March 20, 2025 (GLOBE NEWS

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NCNA_OUT_9 [2025-03-27 16:23:35 -0400] 1099 Bytes | 273 tokens | Cum: 2084 tkns (26.05% of 8k)
==========================================================================

Showing A1 (chunk 2 of 16): WIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the fourth quarter and year ended December 31, 2024 and provided an update on its clinical development program with its two lead anti-cancer medicines.

Get the latest news

delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

"Throughout 2024, we shared multiple data updates from our two lead anti-cancer medicines, NUC-7738 and NUC-3373," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Our lead program, NUC-7738, is a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. Over the past year, we presented data highlighting NUC-7738's potential, when used in combination with pembrolizumab, to redu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NCNA_OUT_11 [2025-03-27 16:23:41 -0400] 1099 Bytes | 261 tokens | Cum: 2481 tkns (31.01% of 8k)
==========================================================================

Showing A1 (chunk 3 of 16): ce tumor volume and prolong progression free survival in PD-1 inhibitor refractory and resistant patients with metastatic melanoma in the NuTide:701 study. Notably, disease control was observed in 75% (9/12) of the patients, five of whom had tumor reductions, with two patients achieving Partial Responses. Seven of the 12 patients had a progression free survival time of greater than five months, which is highly atypical in this patient population. Equally important, the combination has shown a favorable safety profile."

Mr. Griffith added, "Encouraged by these findings, we are excited to further evaluate NUC-7738's potential in an expansion of the NuTide:701 study for patients with PD-1 inhibitor-resistant melanoma. We plan to initiate this expansion study and provide data updates later this year. In addition, we plan to meet with the U.S. Food and Drug Administration to seek guidance on

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NCNA_OUT_13 [2025-03-27 16:23:46 -0400] 1099 Bytes | 264 tokens | Cum: 2854 tkns (35.68% of 8k)
==========================================================================

Showing A1 (chunk 4 of 16): the optimal registration strategy for NUC-7738 as we look to advance it towards approval."

Advertisement

Mr. Griffith continued, "Turning to NUC-3373, our second anti-cancer program is a targeted thymidylate synthase inhibitor with immune modulating properties. It is currently being evaluated in a Phase 1b/2 study known as NuTide:303, which has two separate modules. One module is studying NUC-3373 in combination with pembrolizumab for patients with advanced solid tumors and the second module is studying NUC-3373 with docetaxel for patients with lung cancer. We are excited with the data we have seen from the NuTide:303 study and are particularly encouraged by the significant tumor volume reductions and prolonged progression free survival observed. Two patients achieved Partial Responses, including a patient with urothelial bladder cancer who achieved 100% reduction in their target lesi

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NCNA_OUT_15 [2025-03-27 16:23:51 -0400] 1099 Bytes | 259 tokens | Cum: 3251 tkns (40.64% of 8k)
==========================================================================

Showing A1 (chunk 5 of 16): ons. While we were disappointed with the surprising and unexpected outcome of the NuTide:323 study of NUC-3373 in combination with leucovorin, irinotecan, and bevacizumab in patients with advanced colorectal cancer, we are continuing to evaluate further potential pathways for NUC-3373 in this challenging indication. We look forward to generating further data from this program as we work towards our mission of improving treatment outcomes for patients with cancer which drives our relentless pursuit of the development of new anti-cancer agents."

Mr. Griffith concluded, "In addition to the clinical advancements we have made, we have also strengthened our intellectual property portfolio with the addition of a new granted patent by the United States Patent and Trademark Office covering NUC-7738's composition of matter. Looking ahead in 2025, we are on track to advance both NUC-7738 and NUC-3

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NCNA_OUT_17 [2025-03-27 16:23:53 -0400] 959 Bytes | 294 tokens | Cum: 3637 tkns (45.46% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-08-15T20:01:00Z - NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update
B2 - 2024-05-30T12:36:00Z - NuCana to Present at the Jefferies Global Healthcare Conference
B3 - 2024-05-21T12:00:00Z - NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
B4 - 2024-05-16T20:01:00Z - NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
B5 - 2024-05-01T20:01:00Z - NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement
B6 - 2024-04-09T20:30:00Z - NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NCNA_OUT_19 [2025-03-27 16:24:03 -0400] 741 Bytes | 224 tokens | Cum: 3863 tkns (48.29% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/08/15/2931230/0/en/NuCana-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Business-Update.htmlNuCana reported a net loss of £7.0 million for Q2 2024 and had £11.6 million in cash as of June 30, 2024. The company is advancing its clinical programs, including NUC-3373 and NUC-7738, and expects to announce data readouts in the second half of 2024.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

NCNA_OUT_21 [2025-03-27 16:24:04 -0400] 238 Bytes | 59 tokens | Cum: 4024 tkns (50.30% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NCNA_OUT_23 [2025-03-27 16:24:17 -0400] 3266 Bytes | 844 tokens | Cum: 4871 tkns (60.89% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 256,906 | Perf Month: 13.83% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 115.97K | Perf Quarter: -11.57% | Short Float: 0.17% | ROE: -183.07% |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 2.22 | Index: - | Short Ratio: 0.08 | ROI: -318.25% |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 65.13 | Market Cap: 6.06M | Short Interest: 0.01M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.10 | Shs Outstand: 5.66M | Beta: 1.51 | EPS Surprise: 86.54% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: 24.72% | Shs Float: 5.33M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: 11.97% | Inst Own: 5.88% | Sales past 5Y: 0.00% | Earnings: Mar 20 AMC |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -52.06% | Insider Own: 5.88% | Employees: 22 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: 32.59% | Insider Trans: 0.00% | Debt/Eq: 0.03 | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.07
Average Volume: 67590.83
30-Day High: 1.07
30-Day Low: 0.7605
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

NCNA_OUT_25 [2025-03-27 16:24:20 -0400] 676 Bytes | 167 tokens | Cum: 5282 tkns (66.03% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

NCNA_IN_27 [2025-03-27 16:24:21 -0400] 126 Bytes | 29 tokens | Cum: 5339 tkns (66.74% of 8k)
==========================================================================

====================================
[2025-03-27 13:24:21] # Analysis Completed
Elapsed Time: 74.43 seconds